Kolon Life Science Inc. has terminated a supply contract for Invossa (TC-C; tonogenchoncel-L) in Hong Kong and Macau after South Korea’s drug ministry finalized a decision to revoke its approval of the pioneering cell and gene therapy due to a cell component discrepancy.
The cancellation of the Asian deal raises concerns whether the South Korean firm will be able to maintain other remaining supply and license agreements for Invossa, the first product of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?